A BILL 
To prohibit price gouging in the sale of drugs. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Combatting Unreason-
4
able Rises and Excessively High Drug Prices Act’’ or the 
5
‘‘CURE High Drug Prices Act’’. 
6
SEC. 2. DEFINITIONS. 
7
In this Act: 
8
(1) AVERAGE
MANUFACTURER
PRICE.—The 
9
term ‘‘average manufacturer price’’— 
10
23:39 Aug 15, 2019
H4158
2 
•HR 4158 IH
(A) has the meaning given the term in sec-
1
tion 1927(k) of the Social Security Act (42 
2
U.S.C. 1396r–8(k)); or 
3
(B) with respect to a drug for which there 
4
is no average manufacturer price as so defined, 
5
means the wholesale acquisition cost of the 
6
drug. 
7
(2) DRUG.—The term ‘‘drug’’— 
8
(A) has the meaning given the term in sec-
9
tion 201 of the Federal Food, Drug, and Cos-
10
metic Act (21 U.S.C. 321); and 
11
(B) includes biological products, as defined 
12
in section 351 of the Public Health Service Act 
13
(42 U.S.C. 262). 
14
(3) FEDERAL HEALTH CARE PROGRAM.—The 
15
term ‘‘Federal health care program’’ has the mean-
16
ing given the term in section 1128B(f) of the Social 
17
Security Act (42 U.S.C. 1320a–7b(f)). 
18
(4) MANUFACTURER.—The term ‘‘manufac-
19
turer’’ means a person— 
20
(A) that holds the application for a drug 
21
approved under section 505 of the Federal 
22
Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
23
or the license issued under section 351 of the 
24
Public Health Service Act (42 U.S.C. 262); or 
25
23:39 Aug 15, 2019
H4158
3 
•HR 4158 IH
(B) who is responsible for setting the price 
1
for the drug. 
2
(5) 
PRICE
GOUGING.—The 
term 
‘‘price 
3
gouging’’ means an increase in the average manufac-
4
turer price of a qualifying drug that— 
5
(A) is in substantial excess of an amount 
6
that could be reasonably justified by an increase 
7
in cost of producing the drug or by an increase 
8
in cost due to appropriate expansion of access 
9
to the drug to promote public health; and 
10
(B) because of insufficient competition in 
11
the marketplace, consumers cannot reasonably 
12
avoid. 
13
(6) QUALIFYING DRUG.—The term ‘‘qualifying 
14
drug’’ means any drug, including a combination 
15
product whose primary mode of action is determined 
16
under section 503(g) of the Federal Food, Drug, 
17
and Cosmetic Act (21 U.S.C. 353(g)) to be that of 
18
a drug, that— 
19
(A) is subject to section 503(b)(1) of the 
20
Federal Food, Drug, and Cosmetic Act (21 
21
U.S.C. 353(b)(1)); and 
22
(B) is covered by a Federal health care 
23
program. 
24
23:39 Aug 15, 2019
H4158
4 
•HR 4158 IH
(7) SECRETARY.—The term ‘‘Secretary’’ means 
1
the Secretary of Health and Human Services. 
2
SEC. 3. PRICE GOUGING PROHIBITED. 
3
(a) IN GENERAL.—A manufacturer shall not engage 
4
in price gouging in the sale of a qualifying drug. 
5
(b) PRESUMPTION.—Price gouging shall be presumed 
6
if the average manufacturer price has increased— 
7
(1) 10 percent or more within the previous 12- 
8
month period; 
9
(2) 20 percent or more in the previous 36- 
10
month period; or 
11
(3) 30 percent or more within the previous 60- 
12
month period. 
13
(c) NOTICE BY SECRETARY.—The Secretary shall no-
14
tify the manufacturer of an increase, within the previous 
15
2 years, in the average manufacturer price of a qualifying 
16
drug the Secretary has reason to believe constitutes price 
17
gouging, by sending notice to the manufacturer, request-
18
ing a statement of justification for the increase, which 
19
may include— 
20
(1) itemizing the components of the cost of pro-
21
ducing the qualifying drug; 
22
(2) identifying the circumstances and timing of 
23
an increase in materials or manufacturing costs that 
24
caused an increase in the average manufacturer 
25
23:39 Aug 15, 2019
H4158
5 
•HR 4158 IH
price of the qualifying drug within the 5-year period 
1
preceding the date of the average manufacturer 
2
price increase; 
3
(3) identifying the circumstances and timing of 
4
any expenditures made by the manufacturer to ex-
5
pand access to the qualifying drug and explaining 
6
any improvement in public health associated with 
7
those expenditures; 
8
(4) providing sales and price information for 
9
other qualifying drugs with similar therapeutic ef-
10
fects, as relevant to assessing the extent of competi-
11
tion in the marketplace, and the choice available to 
12
consumers; and 
13
(5) providing any other information that the 
14
manufacturer believes to be relevant to a determina-
15
tion of whether a violation of this Act has occurred. 
16
(d) STATEMENT.—Not later than 45 days after the 
17
date on which a manufacturer receives a statement under 
18
subsection (c), the manufacturer shall submit to the Sec-
19
retary a statement described in subsection (c). 
20
(e) DETERMINATION BY SECRETARY.—If the Sec-
21
retary determines, after review of the statement of jus-
22
tification, or based on reasonable belief if the manufac-
23
turer fails to submit a statement of justification as re-
24
quired, that the manufacturer has engaged in price 
25
23:39 Aug 15, 2019
H4158
6 
•HR 4158 IH
gouging with respect to a qualifying drug, the Secretary 
1
shall notify the manufacturer of the determination. 
2
(f) REMEDY.— 
3
(1) IN
GENERAL.—The Secretary may order 
4
that a manufacturer determined under subsection 
5
(e) to have engaged in price gouging with respect to 
6
a qualifying drug— 
7
(A) restore to any consumer, including a 
8
third-party payor, any excessive amount paid as 
9
a result of a price increase that violates this 
10
Act; 
11
(B) make the drug available to partici-
12
pants of any qualified health plan or Federal 
13
health plan for a period of up to 1 year at the 
14
price at which the drug was made available to 
15
consumers immediately before the violation of 
16
this Act; or 
17
(C) if the price gouging is done knowingly, 
18
or occurs after a previous determination by the 
19
Secretary or price gouging by the manufac-
20
turer, pay a civil penalty of up to 3 times the 
21
excessive amount the manufacturer received as 
22
a result of a violation of this Act. 
23
(2) APPEALS.—Any person adversely affected 
24
by a determination of the Secretary under this sub-
25
23:39 Aug 15, 2019
H4158
7 
•HR 4158 IH
section may obtain review of the determination in 
1
accordance with section 1128A(e) of the Social Secu-
2
rity Act (42 U.S.C. 1320a–7a(e)). 
3
(g) ENFORCEMENT BY ATTORNEY GENERAL.— 
4
(1) IN
GENERAL.—If a manufacturer deter-
5
mined under subsection (e) to have engaged in price 
6
gouging fails to comply with an order of the Sec-
7
retary under subsection (f), the Secretary may refer 
8
the matter to the Attorney General for enforcement. 
9
(2) SUBPOENAS.—The Attorney General may 
10
subpoena documents or testimony as may assist in 
11
establishing whether the manufacturer engaged in 
12
price gouging in violation of this Act. 
13
(3) ACTION.—The Attorney General may bring 
14
an action in an appropriate district court for relief, 
15
including any relief described in subsection (f) and 
16
such further relief as the court determines is appro-
17
priate. 
18
SEC. 4. EFFECTIVE DATE; APPLICABILITY. 
19
This Act shall— 
20
(1) take effect on January 1, 2019; and 
21
(2) apply with respect to all increases in the av-
22
erage manufacturer price of a qualifying drug occur-
23
ring on or after that date. 
24
Æ 
23:39 Aug 15, 2019
H4158
